

TRADEMARK ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

NATURE OF CONVEYANCE:

ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Savient Pharmaceuticals, Inc.		06/30/2005	CORPORATION: DELAWARE

RECEIVING PARTY DATA

Name:	Bio-Technology General (Israel) Ltd.
Street Address:	Kiryat Weizmann
City:	Rehovot
State/Country:	ISRAEL
Postal Code:	76326
Entity Type:	CORPORATION: ISRAEL

PROPERTY NUMBERS Total: 3

Property Type	Number	Word Mark
Serial Number:	78416699	NUFLEXXA
Serial Number:	78416687	NUFLEXA
Serial Number:	78532936	BIOHY

CORRESPONDENCE DATA

Fax Number: (212)425-5288
Correspondence will be sent via US Mail when the fax attempt is unsuccessful.
Phone: 212-425-7200
Email: tmdocketny@kenyon.com
Correspondent Name: Asiyah McCarthy
Address Line 1: One Broadway
Address Line 4: New York, NEW YORK 10004

DOMESTIC REPRESENTATIVE

Name: Howard J. Shire, Esq.
Address Line 1: One Broadway
Address Line 4: New York, NEW YORK 10004

TRADEMARK

900027870

REEL: 003118 FRAME: 0105

CH \$90.00 78416699

NAME OF SUBMITTER:	Howard J. Shire, Esq.
Signature:	/Howard J. Shire/
Date:	07/07/2005
Total Attachments: 3 source=nuflexxa assignment#page1.tif source=nuflexxa assignment#page2.tif source=nuflexxa assignment#page3.tif	

TRADEMARK ASSIGNMENT

This Trademark Assignment is made and effective on June 30, 2005, and is from **Savient Pharmaceuticals, Inc.**, a corporation organized and existing under the laws of the state of Delaware and having an office at One Tower Center Boulevard, 14th Floor East Brunswick, New Jersey 08816 (hereinafter the ASSIGNOR), to **Bio-Technology General (Israel) Ltd.**, a corporation organized and by existing under the laws of Israel, having an office at Kiryat Weizmann, 76326 Rehovot, Israel (hereinafter the ASSIGNEE):

WITNESSETH THAT:

WHEREAS, ASSIGNOR is the owner of all right, title and interest in and to the trademark applications listed on the attached Schedule A (collectively, the "Marks"), including without limitation any goodwill of the business appurtenant to and symbolized by the Marks, and any common law rights in and to the Marks; and

WHEREAS, ASSIGNEE is the successor to the portion of ASSIGNOR'S business to which the Marks pertain and wishes to acquire from ASSIGNOR any and all right, title and interest in and to the Marks, together with any and all goodwill of the business appurtenant to and symbolized by the Marks, and any and all common law rights in and to the Marks;

NOW, THEREFORE, in consideration of the promises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, ASSIGNOR hereby assigns, sells, and transfers unto ASSIGNEE, all right, title and interest in and to the Marks together with any goodwill of the business appurtenant to and symbolized by the Marks, any common law rights in and to the Marks and the right to sue and recover for, and the right to profits or damages due or accrued arising out of or in connection with, any and all past, present or future infringements or dilution of or damage or injury to the Marks, to be held and

enjoyed by ASSIGNEE, its successors and assigns to the same extent that such would have been held and enjoyed by ASSIGNOR had such assignment not been made.

ASSIGNOR assigns the Marks as part of that portion of the business to which the Marks pertain as required by Section 10 of the U.S. Trademark Act (15 U.S.C. § 1060).

Savient Pharmaceuticals, Inc.

Dated: June 30, 2005

By: 

Name:

Title:

Philip K. Yachmetz
SVP - Corporate Strategy
General Counsel

SCHEDULE A

<u>MARK</u>	<u>SERIAL NUMBER</u>	<u>FILING DATE</u>
NUFLEXA	78/416,699	May 11, 2004
NUFLEXA	78/416,687	May 11, 2004
BIOHY	78/532,936	December 15, 2004

1014445v1